Ariadne Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$834K Hold
5,319
0.37% 68
2026
Q1
$812K Hold
5,319
0.36% 63
2025
Q4
$857K Sell
5,319
-371
-7% -$48.6K 0.35% 64
2025
Q3
$751K Buy
5,690
+282
+5% +$34.4K 0.34% 67
2025
Q2
$655K Sell
5,408
-104
-2% -$11.7K 0.31% 68
2025
Q1
$599K Sell
5,512
-582
-10% -$62K 0.31% 73
2024
Q4
$651K Buy
6,094
+727
+14% +$77.5K 0.3% 66
2024
Q3
$575K Buy
+5,367
New +$609K 0.31% 60

Other funds holding NVS

Ariadne Wealth Management's NVS Position: Q2 2026 in Review

Ariadne Wealth Management held its Novartis (NVS) position steady in Q2 2026 at 5,319 shares worth $834K. The position accounts for 0.37% of the portfolio, ranked #68.

Ariadne Wealth Management first reported a position in NVS in Q3 2024 and has held it in 8 quarters since. The position peaked at $857K in Q4 2025. 1,621 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Ariadne Wealth Management held 5,319 shares of Novartis worth $834K as of Q2 2026.
  • Ariadne Wealth Management left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.37% of Ariadne Wealth Management's portfolio in Q2 2026, its #68 holding.
  • Ariadne Wealth Management first reported a position in Novartis in Q3 2024 and has held it in 8 quarters since.
  • Ariadne Wealth Management's Novartis position peaked at $857K in Q4 2025.
  • 1,621 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Ariadne Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.